sterna biologicals successfully completes Phase I development programme of SB010
Marburg, Germany, 11 September 2012
SB010 was safe and well-tolerated across all dose levels
Phase IIa proof-of-concept trial filed with regulatory agencies
sterna biologicals GmbH & Co. KG (“sterna biologicals”) announced today that SB010, a DNAyzme-based GATA-3 antagonist for the treatment of moderate to severe Th2-driven asthma, successfully completed its comprehensive Phase I development programme.